Lung Cancer
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Read More
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Listen
FDA Approves Adjuvant Alectinib in ALK+ NSCLC
The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer
Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.